SELLAS Life Sciences

October 21, 2016October 21, 2016

Sellas Life Sciences Names Jonathan Eckard as New Chief Business and Strategy Officer

News

Sellas Life Sciences recently named Jonathan Eckard, PhD, as its chief business and strategy officer. Eckard’s doctorate in toxicology and carcinogenesis is from NYU School of Medicine, where he also earned a master’s ... Read more

September 20, 2016September 20, 2016

FDA Moves Galinpepimut-S, Potential Immunotherapy for Malignant Pleural Mesothelioma, to ‘Fast Track’

News

The U.S. Food and Drug Administration has granted Fast Track designation to SELLAS Life Sciences‘ WT1 cancer vaccine — galinpepimut-S — as a possible treatment of malignant pleural mesothelioma. This action ... Read more

April 8, 2016April 8, 2016

COMP Favors Orphan Drug Designation for SELLAS’ WT1 Vaccine to Treat MPM

News

The Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMA) has given a positive opinion in support of orphan drug designation for the WT1 cancer vaccine (galinpepimut-S), which SELLAS Life ... Read more

April 7, 2016April 7, 2016

SELLAS to Present Mesothelioma Phase 2 Trial Results of Cancer Vaccine at Upcoming Meetings

News

SELLAS Life Sciences Group announced that it will present the results of a Phase 2 clinical trial evaluating the WT1 cancer vaccine in patients with malignant pleural mesothelioma (MPM) at the 13th ... Read more

December 8, 2015December 8, 2015

Positive WT1 Cancer Vaccine Clinical Trial Results For Mesothelioma, Other Cancers Reported At International WT1 Conference

News

Zug, Switzerland, based SELLAS Life Sciences Group, (SELLAS), a 2012 startup clinical-stage biopharmaceutical company focused on development of novel cancer therapies, reports that positive data from the company’s clinical studies ... Read more